Clinical Trial Update: Open Label Tolerability and Safety Study of KRX-101 in Australia, New Zealand, and Hong Kong [Phase 3]

View source ↗

Summary

Open-label Phase 3 tolerability and safety study of KRX-101 in diabetic nephropathy was terminated in Australia, New Zealand, and Hong Kong.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Nephropathy

Drugs mentioned

• KRX-101

Snippet

Sponsor: Keryx Biopharmaceuticals | Conditions: Diabetic Nephropathy | Phase 3 | Status: TERMINATED